Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Circulation Research

• Publication date

  2014-06-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1161/CIRCRESAHA.115.302922PMID 24951759PMCID PMC4146618
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• High Prevalence of Occult Pulmonary Venous Hypertension Revealed by Fluid Challenge in Pulmonary Hypertension

  2014cited by this paper
• Impaired systolic function by strain imaging in heart failure with preserved ejection fraction.

  2014influential reference
• Gigantic Business: Titin Properties and Function Through Thick and Thin

  2014cited by this paper
• Refining calcium test for diagnosis of medullary thyroid cancer: cutoffs, procedures and safety

  2014cited by this paper
• Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction.

  2014cited by this paper
• Current role of neprilysin inhibitors in hypertension and heart failure.

  2014cited by this paper
• Mechanisms of exercise-induced cardioprotection.

  2014cited by this paper
• Faculty Opinions recommendation of A controlled trial of renal denervation for resistant hypertension.

  2014cited by this paper
• Spironolactone for heart failure with preserved ejection fraction.

  2014influential reference
• Role of inflammation in the pathogenesis of heart failure with preserved ejection fraction and its potential as a therapeutic target

  2014cited by this paper
• Skeletal muscle abnormalities and exercise intolerance in older patients with heart failure and preserved ejection fraction.

  2014cited by this paper
• S-glutathionylation of cryptic cysteines enhances titin elasticity by blocking protein folding.

  2014cited by this paper
• Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction: Baseline Findings From the Echocardiographic Study of the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial

  2014cited by this paper
• Cardiomyocyte-Specific Transforming Growth Factor &bgr; Suppression Blocks Neutrophil Infiltration, Augments Multiple Cytoprotective Cascades, and Reduces Early Mortality After Myocardial Infarction

  2014cited by this paper
• Invasive assessment of pulmonary hypertension: time for a more fluid approach?

  2014cited by this paper
• Spinal Cord Stimulation for Heart Failure: Preclinical Studies to Determine Optimal Stimulation Parameters for Clinical Efficacy

  2014cited by this paper
• Prognostic Importance of Pathophysiologic Markers in Patients With Heart Failure and Preserved Ejection Fraction

  2014influential reference
• Heart failure with preserved ejection fraction: molecular pathways of the aging myocardium.

  2014cited by this paper
• Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial.

  2013cited by this paper
• Myocardial Titin Hypophosphorylation Importantly Contributes to Heart Failure With Preserved Ejection Fraction in a Rat Metabolic Risk Model

  2013cited by this paper
• Role of oxidants on calcium and sodium movement in healthy and diseased cardiac myocytes.

  2013cited by this paper
• Matchmaking for the optimization of clinical trials of heart failure with preserved ejection fraction: no laughing matter.

  2013cited by this paper
• Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial.

  2013cited by this paper
• B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction.

  2013cited by this paper
• Prevalence of Symptomatic Heart Failure with Reduced and with Normal Ejection Fraction in an Elderly General Population–The CARLA Study

  2013cited by this paper
• Impaired aerobic capacity and physical functional performance in older heart failure patients with preserved ejection fraction: role of lean body mass.

  2013cited by this paper
• Comparison of predictors of heart failure-related hospitalization or death in patients with versus without preserved left ventricular ejection fraction.

  2013cited by this paper
• Sildenafil and exercise capacity in heart failure.

  2013cited by this paper
• Crucial Role for Ca2+/Calmodulin-Dependent Protein Kinase-II in Regulating Diastolic Stress of Normal and Failing Hearts via Titin Phosphorylation

  2013cited by this paper
• Biomarkers of Diastolic Dysfunction and Myocardial Fibrosis: Application to Heart Failure with a Preserved Ejection Fraction

  2013cited by this paper
• Disease management: remote monitoring in heart failure patients with implantable defibrillators, resynchronization devices, and haemodynamic monitors.

  2013cited by this paper
• Baseline Characteristics of Patients in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial

  2013cited by this paper
• Therapeutic potential of renal sympathetic denervation in patients with chronic heart failure.

  2013cited by this paper
• Abdominal contributions to cardiorenal dysfunction in congestive heart failure.

  2013cited by this paper
• Heart rate reduction by If-inhibition improves vascular stiffness and left ventricular systolic and diastolic function in a mouse model of heart failure with preserved ejection fraction.

  2013cited by this paper
• 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

  2013cited by this paper
• Focused Update : ACCF / AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults

  2013cited by this paper
• Circulating Biomarkers in Patients with Heart Failure and Preserved Ejection Fraction

  2013cited by this paper
• How do patients with heart failure with preserved ejection fraction die?

  2013cited by this paper
• Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J‐DHF)

  2013cited by this paper
• A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation.

  2013cited by this paper
• Effect of endurance exercise training on endothelial function and arterial stiffness in older patients with heart failure and preserved ejection fraction: a randomized, controlled, single-blind trial.

  2013cited by this paper
• Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.

  2013cited by this paper
• Heart disease and stroke statistics--2013 update: a report from the American Heart Association.

  2013cited by this paper
• Biomarkers in acutely decompensated heart failure with preserved or reduced ejection fraction.

  2012influential reference
• Effects of the long‐term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study

  2012cited by this paper
• Low Myocardial Protein Kinase G Activity in Heart Failure With Preserved Ejection Fraction

  2012cited by this paper
• Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction.

  2012cited by this paper
• Pressure-Overload–Induced Subcellular Relocalization/Oxidation of Soluble Guanylyl Cyclase in the Heart Modulates Enzyme Stimulation

  2012cited by this paper
• Urinary albumin excretion in heart failure with preserved ejection fraction: an interim analysis of the CHART 2 study

  2012cited by this paper
• Review: Heart failure with preserved ejection fraction in African Americans.

  2012cited by this paper
• The Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Heart Failure with Preserved Ejection Fraction: A Phase II Randomised-Controlled Trial

  2012cited by this paper
• Circulation Editors' Picks: Most Read Articles in Heart Failure

  2012cited by this paper
• ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012

  2012cited by this paper
• The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.

  2012cited by this paper
• Trends in Patients Hospitalized With Heart Failure and Preserved Left Ventricular Ejection Fraction: Prevalence, Therapies, and Outcomes

  2012cited by this paper
• Pulmonary Capillary Wedge Pressure Augments Right Ventricular Pulsatile Loading

  2012cited by this paper
• Cardiac transthyretin amyloidosis

  2012cited by this paper
• A TRPC6-dependent pathway for myofibroblast transdifferentiation and wound healing in vivo.

  2012cited by this paper
• Rationale and study design of the increase of vagal tone in heart failure study: INOVATE-HF.

  2012cited by this paper
• Renal Sympathetic Denervation for Treatment of Drug-Resistant Hypertension: One-Year Results From the Symplicity HTN-2 Randomized, Controlled Trial

  2012cited by this paper
• Effects of Percutaneous Stimulation of Both Sympathetic and Parasympathetic Cardiac Autonomic Nerves on Cardiac Function in Dogs

  2012cited by this paper
• Prognostic utility of ST2 in patients with acute dyspnea and preserved left ventricular ejection fraction.

  2011cited by this paper
• 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.

  2011cited by this paper
• Quality of life is impaired similarly in heart failure patients with preserved and reduced ejection fraction

  2011cited by this paper
• Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction: results of the Ex-DHF (Exercise training in Diastolic Heart Failure) pilot study.

  2011cited by this paper
• TRPC Channels As Effectors of Cardiac Hypertrophy

  2011cited by this paper
• Pentraxin 3 is a new inflammatory marker correlated with left ventricular diastolic dysfunction and heart failure with normal ejection fraction.

  2011cited by this paper
• Can emerging biomarkers of myocardial remodelling identify asymptomatic hypertensive patients at risk for diastolic dysfunction and diastolic heart failure?

  2011cited by this paper
• Results of the Randomized Aldosterone Antagonism in Heart Failure with Preserved Ejection Fraction trial (RAAM-PEF).

  2011cited by this paper
• Chronic vagus nerve stimulation: a new and promising therapeutic approach for chronic heart failure.

  2011cited by this paper
• Diastolic tissue Doppler indexes correlate with the degree of collagen expression and cross-linking in heart failure and normal ejection fraction.

  2011cited by this paper
• Pivotal role of cardiomyocyte TGF-β signaling in the murine pathological response to sustained pressure overload.

  2011cited by this paper
• Renal function and long-term survival after hospital discharge in heart failure with preserved ejection fraction.

  2011cited by this paper
• Cardiac Inflammation Contributes to Changes in the Extracellular Matrix in Patients With Heart Failure and Normal Ejection Fraction

  2011cited by this paper
• Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial.

  2011cited by this paper
• Ventricular-vascular interaction in heart failure.

  2011cited by this paper
• Pressure-volume relation analysis of mouse ventricular function.

  2011cited by this paper
• Contribution of comorbidities to functional impairment is higher in heart failure with preserved than with reduced ejection fraction

  2011cited by this paper
• Abnormal haemodynamic response to exercise in heart failure with preserved ejection fraction

  2011cited by this paper
• Direct Left Atrial Pressure Monitoring in Severe Heart Failure: Long-Term Sensor Performance

  2010cited by this paper
• Exercise Hemodynamics Enhance Diagnosis of Early Heart Failure With Preserved Ejection Fraction

  2010cited by this paper
• HFSA 2010 Comprehensive Heart Failure Practice Guideline.

  2010cited by this paper
• Filling Pressures and Collagen Metabolism in Hypertensive Patients With Heart Failure and Normal Ejection Fraction

  2010cited by this paper
• Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction.

  2010cited by this paper
• TRPC6 channels and their binding partners in podocytes: role in glomerular filtration and pathophysiology.

  2010cited by this paper
• Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial.

  2010cited by this paper
• Heart failure with preserved ejection fraction in outpatients with unexplained dyspnea: a pressure-volume loop analysis.

  2010cited by this paper
• Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study.

  2010cited by this paper
• Pharmacokinetics and Pharmacodynamics of LCZ696, a Novel Dual‐Acting Angiotensin Receptor—Neprilysin Inhibitor (ARNi)

  2010cited by this paper
• Exercise Training in Older Patients With Heart Failure and Preserved Ejection Fraction: A Randomized, Controlled, Single-Blind Trial

  2010cited by this paper
• Heart rate reduction by I(f)-channel inhibition and its potential role in heart failure with reduced and preserved ejection fraction.

  2009cited by this paper
• Blunted frequency-dependent upregulation of cardiac output is related to impaired relaxation in diastolic heart failure

  2009cited by this paper
• Relation of Disease Pathogenesis and Risk Factors to Heart Failure With Preserved or Reduced Ejection Fraction: Insights From the Framingham Heart Study of the National Heart, Lung, and Blood Institute

  2009cited by this paper
• Phosphodiesterase-5 Inhibitor, Tadalafil, Protects Against Myocardial Ischemia/Reperfusion Through Protein-Kinase G–Dependent Generation of Hydrogen Sulfide

  2009cited by this paper
• Modulation of titin-based stiffness by disulfide bonding in the cardiac titin N2-B unique sequence.

  2009cited by this paper
• Heart failure with preserved ejection fraction is characterized by dynamic impairment of active relaxation and contraction of the left ventricle on exercise and associated with myocardial energy deficiency.

  2009cited by this paper
• Inflammatory Markers and Incident Heart Failure Risk in Older Adults: The Health, Aging, and Body Composition Study

  2009cited by this paper
• Impaired Heart Rate Recovery and Chronotropic Incompetence in Patients With Heart Failure With Preserved Ejection Fraction

  2009cited by this paper
• Pressure-overload magnitude-dependence of the anti-hypertrophic efficacy of PDE5A inhibition.

  2009cited by this paper

• Attenuated Peripheral Vascular Responsiveness Contributes to Baroreflex Dysfunction in Patients with Wild-Type Transthyretin Amyloidosis (wtATTR).

  2026cites this paper
• Frailty Status Predicts Adverse Outcomes in Ambulatory Heart Failure With Preserved Ejection Fraction.

  2026cites this paper
• Renal Function and Left Ventricular Ejection Fraction in Diabetic Patients with Acute Heart Failure

  2026cites this paper
• Modulating CGRP Signaling: A Promising Therapeutic Avenue for Attenuating Cardiac Dysfunction in Heart Failure.

  2026cites this paper
• Effects of Heat Therapy on Exercise Tolerance in a Rat Model of Heart Failure with Preserved Ejection Fraction.

  2025cites this paper
• Molecular Mechanisms of L-Type Calcium Channel Dysregulation in Heart Failure

  2025cites this paper
• Hypertensive heart disease: is it really a pathology?

  2025cites this paper
• Beyond Leptin and Adiponectin: The Diverse Roles of Adipokines in the Myocardial Hypertrophic Process and Heart Failure and Their Potential Contribution in Obesity

  2025cites this paper
• Baicalin: an active natural product with potential medicinal values

  2025cites this paper
• The Role of Renal Denervation in HFpEF

  2025cites this paper
• Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography and for Heart Failure With Preserved Ejection Fraction Diagnosis: An Update From the American Society of Echocardiography.

  2025cites this paper
• Recent Insights into the Relationship Between Sleep Disordered Breathing and Cardiovascular Disease.

  2025cites this paper
• Longitudinal changes in circulating cyclic guanosine monophosphate in women over the menopause transition compared to men: the Coronary Artery Risk Development in Young Adults (CARDIA) study

  2025cites this paper
• Inflammasomes in Cardiovascular Diseases: Current Knowledge and Future Perspectives

  2025cites this paper
• FGF21 protects against HFpEF by improving cardiac mitochondrial bioenergetics in mice

  2025cites this paper
• Cardiac Remodeling and Functional Alterations in Heart Failure With Preserved Ejection Fraction (HFpEF): An Echocardiographic Assessment at a Tertiary Hospital in Bangladesh

  2025cites this paper
• Persistent Fibrosis and Left Ventricular Chamber Stiffening Despite Cessation of Repetitive Pressure Overload in Swine

  2025cites this paper
• Critical appraisal of early diagnosis and progression to heart failure with preserved ejection fraction among hypertensive patients with left ventricular hypertrophy.

  2025cites this paper
• GRK2 and GRK5-The 2 critical kinases in cardiac pathophysiology.

  2025cites this paper
• Association Between Cardiopulmonary Fitness and Degenerative Lumbar Spine Disease in Patients with Heart Failure: a Retrospective Study Using CPET

  2025cites this paper
• Molecular Mechanisms Underlying Heart Failure and Their Therapeutic Potential

  2025cites this paper
• Editorial: Cardiovascular immunometabolism - a complex interplay between the immune system and metabolism in the heart

  2025cites this paper
• NT-proBNP in Heart Failure with Preserved Ejection Fraction: A Comprehensive Review

  2024cites this paper
• JCS 2023 Guideline on Diagnosis and Treatment of Sleep Disordered Breathing in Cardiovascular Disease.

  2024cites this paper
• Vitamin B6 prevents heart failure with preserved ejection fraction through downstream of kinase 3 in a mouse model.

  2024cites this paper
• Diabetes mellitus does not alter mortality or hospitalisation risk in patients with newly diagnosed heart failure with preserved ejection fraction: Time to rethink pathophysiological models of disease progression

  2024cites this paper
• Innate immune memory after brain injury drives inflammatory cardiac dysfunction.

  2024cites this paper
• Does Cell-Type-Specific Silencing of Monoamine Oxidase B Interfere with the Development of Right Ventricle (RV) Hypertrophy or Right Ventricle Failure in Pulmonary Hypertension?

  2024cites this paper
• Macrophage-to-myofibroblast transition and its role in cardiac fibrosis.

  2024cites this paper
• Porcine Model of Hypertrophy-Independent Left Ventricular Stiffening via Repetitive Pressure Overload.

  2024cites this paper
• The impact of empagliflozin and metformin on cardiac parameters in patients with mid-range ejection fraction heart failure without diabetes

  2024cites this paper
• Precision Cardiology: Phenotype-targeted Therapies for HFmrEF and HFpEF.

  2024cites this paper
• Clinical utility of the Fibrosis-4 index for predicting mortality in patients with heart failure with or without metabolic dysfunction-associated steatotic liver disease: a prospective cohort study

  2024cites this paper
• Stromal Cell-SLIT3/Cardiomyocyte-ROBO1 Axis Regulates Pressure Overload-Induced Cardiac Hypertrophy

  2024cites this paper
• 2024 Guidelines of the Taiwan Society of Cardiology for the Diagnosis and Treatment of Heart Failure with Preserved Ejection Fraction.

  2024cites this paper
• Macrophage-based therapeutic approaches for cardiovascular diseases

  2024cites this paper
• Endurance Exercise Training Mitigates Diastolic Dysfunction in Diabetic Mice Independent of Phosphorylation of Ulk1 at S555

  2024cites this paper
• Cardiovascular complications of rheumatoid arthritis.

  2024cites this paper
• Mechanism-based myofilament manipulation to treat diastolic dysfunction in HFpEF

  2024cites this paper
• Roles of cMyBP-C phosphorylation on cardiac contractile dysfunction in db/db mice

  2024cites this paper
• Reversal of contractile defects by mediating calcium homeostasis in human mini-heart models of heart failure with preserved ejection fraction (HFpEF) leads to first-in-human gene therapy clinical trial

  2024cites this paper
• Loss of glymphatic homeostasis in heart failure

  2024cites this paper
• Diastolic dysfunction is an independent predictor for cardiovascular events after an acute kidney injury.

  2023cites this paper
• A Study of Iron Profile in Patients with Heart Failure with Preserved and Reduced Ejection Fraction

  2023cites this paper
• A numerical study of a left ventricular expander for heart failure with preserved ejection fraction

  2023cites this paper
• Renal injury in relation to obesity and the additive effect of hypertension in female and male obese and lean ZSF1 rats.

  2023cites this paper
• Imaging Early Life Cardiovascular Phenotype

  2023cites this paper
• Left ventricular remodeling in rheumatoid arthritis patients without clinical heart failure

  2023cites this paper
• Renal Denervation Helps Preserve the Ejection Fraction by Preserving Endocardial-Endothelial Function during Heart Failure

  2023cites this paper
• Simulating hyperelasticity and fractional viscoelasticity in the human heart

  2023cites this paper
• Childhood household dysfunction is associated with reduced left ventricular mass in young adulthood.

  2023cites this paper
• Regulation of Hypoxic–Adenosinergic Signaling by Estrogen: Implications for Microvascular Injury

  2023cites this paper
• Physical Therapy for Adults with Heart Failure

  2023cites this paper
• Acute Decompensated Heart Failure with Preserved Ejection Fraction: Do the Asian Phenotypes Fit?

  2023cites this paper
• The link between immunity and hypertension in the kidney and heart

  2023cites this paper
• Supervised Exercise Training for Chronic Heart Failure With Preserved Ejection Fraction: A Scientific Statement From the American Heart Association and American College of Cardiology

  2023cites this paper
• Reverse electrical remodeling in rats with heart failure and preserved ejection fraction

  2023cites this paper
• Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype.

  2023cites this paper
• Clinical and Mechanistic Potential of Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors in Heart Failure with Preserved Ejection Fraction.

  2023cites this paper
• Breathe Better and Preserve Heart

  2023cites this paper
• Fatty liver disease, heart rate and cardiac remodelling: Evidence from the UK Biobank

  2023cites this paper
• Supervised Exercise Training for Chronic Heart Failure With Preserved Ejection Fraction: A Scientific Statement From the American Heart Association and American College of Cardiology.

  2023cites this paper
• The Value of Neutrophil-to-Lymphocyte Ratio and Epicardial Adipose Tissue Thickness in Heart Failure With Preserved Ejection Fraction

  2023cites this paper
• Liraglutide protects against diastolic dysfunction and improves ventricular protein translation

  2023cites this paper
• Hepatocyte Growth Factor and 10-Year Change in Left Ventricular Structure: The Multi-Ethnic Study of Atherosclerosis (MESA)

  2023cites this paper
• Thymosin beta-4 denotes new directions towards developing prosperous anti-aging regenerative therapies.

  2023cites this paper
• Obesity-Related Differences in Pathomechanism and Outcomes in Patients With HFpEF

  2023cites this paper
• A Literature Review on the Coexisting Chronic Obstructive Pulmonary Disease and Heart Failure

  2023cites this paper
• Galectin -3: an independent cardiac marker of left ventricular (LV) remodeling in chronic heart failure

  2023cites this paper
• Caloric Restriction Rejuvenates Skeletal Muscle Growth in Heart Failure With Preserved Ejection Fraction

  2023cites this paper
• Computational modeling of ventricular-ventricular interactions suggest a role in clinical conditions involving heart failure

  2023cites this paper
• Qiliqiangxin capsule improves cardiac remodeling in rats with DOCA-salt-induced diastolic dysfunction.

  2023cites this paper
• Innate immune memory after brain injury drives inflammatory cardiac dysfunction

  2023cites this paper
• Metformin effects on cardiac parameters in non-diabetic Iraqi patients with heart failure and mid-range ejection fraction – a comparative two-arm parallel clinical study

  2023cites this paper
• The relationship of systemic and pulmonary arterial parameters with HFpEF scores (H2FPEF, HFA‐PEFF) and diastolic dysfunction parameters in heart failure patients with preserved ejection fraction

  2023cites this paper
• Heart Failure with Preserved Ejection Fraction and Cancer

  2022cites this paper
• Heart Failure and Pulmonary Hypertension

  2022cites this paper
• Angiopoietins, vascular endothelial growth factors and secretory phospholipase A2 in heart failure patients with preserved ejection fraction.

  2022cites this paper
• Non-invasive assessment of HFpEF in mouse models: current gaps and future directions

  2022cites this paper
• The Efficacy of Nitrite Therapy for the Treatment of Heart Failure: A Meta-Analysis of Randomized Controlled Trials.

  2022cites this paper
• Mitochondrial oxidative stress contributes to diastolic dysfunction through impaired mitochondrial dynamics

  2022cites this paper
• Glifozins and Atrial Fibrillation.

  2022cites this paper
• 30-day readmission in patients with heart failure with preserved ejection fraction: Insights from the nationwide readmission database

  2022cites this paper
• Neurocognitive Benefit of Weight-Loss Interventions in Older Patients with Heart Failure with Preserved Ejection Fraction

  2022cites this paper
• Modeling heart failure with preserved ejection fraction in rodents: Where do we stand?

  2022cites this paper
• Usefulness of P‐wave peak time as an electrocardiographic parameter in predicting left ventricular diastolic dysfunction in patients with mitral regurgitation

  2022influential citation
• Crosstalk between cytotoxic CD8+ T cells and stressed cardiomyocytes triggers development of interstitial cardiac fibrosis in hypertensive mouse hearts

  2022cites this paper
• The fibrosis‐4 score is associated with long‐term mortality in different phenotypes of acute heart failure

  2022cites this paper
• Sex-specific responses to slow progressive pressure overload in a large animal model of HFpEF

  2022cites this paper
• Association between periodontitis and heart failure in the general population

  2022cites this paper
• What is actually preserved in HFpEF? Focus on myocyte calcium handling remodelling.

  2022cites this paper
• Hemorrhagic ascites as a complication of heart failure: A case report and review of the literature

  2022cites this paper
• Periplocin Alleviates Cardiac Remodeling in DOCA-Salt–Induced Heart Failure Rats

  2022cites this paper
• Spironolactone Utilization among Patients with Reduced and Preserved Ejection Fraction Heart Failure

  2022influential citation
• Pharmacological mechanisms of sodium-glucose co-transporter 2 inhibitors in heart failure with preserved ejection fraction

  2022cites this paper
• Atrial fibrillation is an independent risk factor for heart failure hospitalization in heart failure with preserved ejection fraction

  2022cites this paper
• Early Protective Role of Inflammation in Cardiac Remodeling and Heart Failure: Focus on TNFα and Resident Macrophages

  2022cites this paper
• Nuanxinkang protects against ischemia/reperfusion-induced heart failure through regulating IKKβ/IκBα/NF-κB-mediated macrophage polarization.

  2022cites this paper
• Estimation of Functional Aerobic Capacity Using the Sit-to-Stand Test in Older Adults with Heart Failure with Preserved Ejection Fraction

  2022cites this paper
• Phenotypes of heart failure with preserved ejection fraction and effect of spironolactone treatment

  2022influential citation